Abstract
The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Current Drug Targets
Title: Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Volume: 6 Issue: 1
Author(s): A. Forte, M. Cipollaro, A. Cascino and U. Galderisi
Affiliation:
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Abstract: The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Export Options
About this article
Cite this article as:
Forte A., Cipollaro M., Cascino A. and Galderisi U., Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases, Current Drug Targets 2005; 6 (1) . https://dx.doi.org/10.2174/1389450053344920
DOI https://dx.doi.org/10.2174/1389450053344920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Role of Ascorbic Acid in Cardiovascular Performance During Acute Hemorrhage
Vascular Disease Prevention (Discontinued) Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
Current Pharmaceutical Design Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins
Current Organic Chemistry Prevention of Contrast Induced Nephropathy
Current Drug Therapy Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Childhood Solitary Cutaneous Mastocytoma: Clinical Manifestations, Diagnosis, Evaluation, and Management
Current Pediatric Reviews A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Inflammatory Reactions and Hydrocortisone in the Setting of Cardiac Surgery: An Overview
Cardiovascular & Hematological Agents in Medicinal Chemistry The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology